Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19035354 | ANTI-TRANSFERRIN RECEPTOR ANTIBODIES, CONJUGATES THEREOF, AND USES THEREOF | January 2025 | September 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 18999104 | TREM2 STABILIZING ANTIBODIES | December 2024 | December 2025 | Allow | 12 | 1 | 0 | Yes | No |
| 18919082 | COMPOSITIONS FOR TREATING CANCER | October 2024 | June 2025 | Allow | 8 | 1 | 1 | No | No |
| 18897951 | BISPECIFIC ANTIBODIES TARGETING PD1 AND VEGF | September 2024 | June 2025 | Allow | 8 | 1 | 0 | No | No |
| 18290171 | ANTI-TIGIT ANTIBODIES AND USE THEREOF | September 2024 | October 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18746792 | LAG-3 COMBINATION THERAPY FOR THE TREATMENT OF CANCER | June 2024 | September 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18660672 | ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF | May 2024 | April 2025 | Allow | 11 | 1 | 1 | No | No |
| 18656081 | ANTIBODIES THAT BIND PSMA AND GAMMA-DELTA T CELL RECEPTORS | May 2024 | June 2025 | Allow | 13 | 1 | 0 | No | No |
| 18018536 | ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOF | January 2023 | August 2025 | Abandon | 31 | 1 | 1 | No | No |
| 18152595 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | January 2023 | November 2025 | Allow | 35 | 2 | 1 | No | No |
| 18014457 | ANTIBODIES THAT BIND PSMA AND GAMMA-DELTA T CELL RECEPTORS | January 2023 | November 2025 | Abandon | 34 | 1 | 1 | No | No |
| 18065472 | ANTI-TAU ANTIBODIES AND METHODS OF USE | December 2022 | August 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 18064081 | DOSING OF POLYOMAVIRUS NEUTRALIZING ANTIBODIES | December 2022 | March 2026 | Abandon | 39 | 1 | 0 | No | No |
| 17993654 | Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies | November 2022 | June 2025 | Abandon | 31 | 3 | 0 | Yes | No |
| 18058167 | METHODS FOR PREVENTING, REVERSING OR TREATING AN INFECTION INDUCED BY A VIRUS THAT ENTERS HOST CELLS VIA ACE2 RECEPTOR | November 2022 | September 2025 | Abandon | 34 | 2 | 0 | No | No |
| 17871397 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | July 2022 | December 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17771367 | ANTI-CD40 BINDING MOLECULES AND BI-SPECIFIC ANTIBODIES COMPRISING SUCH | April 2022 | February 2026 | Allow | 46 | 1 | 0 | No | No |
| 17548340 | Antineoplastic Combinations with m-TOR Inhibitor, Trastuzumab and/or HKI-272 | December 2021 | September 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17613122 | CRA4S1 GENE, ENCODED CRA4S1 PROTEIN, AND APPLICATION | November 2021 | December 2025 | Allow | 49 | 3 | 0 | Yes | No |
| 17612954 | ANTIBODIES THAT BIND HUMAN METAPNEUMOVIRUS FUSION PROTEIN AND THEIR USE | November 2021 | October 2025 | Allow | 47 | 1 | 0 | No | No |
| 16972895 | SET OF REAGENTS FOR DETECTING A MARKER OF EPITHELIAL CARCINOMAS | November 2021 | June 2025 | Abandon | 54 | 1 | 0 | No | No |
| 17441706 | ANTIGEN-BINDING AGENTS THAT SPECIFICALLY BIND EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III | September 2021 | November 2025 | Allow | 50 | 1 | 0 | No | No |
| 17436934 | T CELL RECEPTORS AND METHODS OF USE THEREOF | September 2021 | August 2025 | Allow | 48 | 1 | 0 | No | No |
| 17434286 | THERAPEUTIC ANTIGEN BINDING PROTEINS SPECIFIC FOR CD93 AND METHODS OF USE THEREOF | August 2021 | April 2025 | Allow | 44 | 1 | 0 | No | No |
| 17428650 | METHODS AND COMPOSITIONS FOR TREATING CANCER | August 2021 | January 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17425870 | NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES | July 2021 | March 2026 | Allow | 55 | 2 | 1 | No | No |
| 17424691 | IMMUNOGLOBULIN PURIFICATION METHOD AND IMMUNOGLOBULIN PURIFICATION DEVICE, AND IMMUNOGLOBULIN PRODUCTION METHOD AND IMMUNOGLOBULIN PRODUCTION DEVICE | July 2021 | October 2025 | Abandon | 51 | 2 | 0 | No | No |
| 17380483 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY, DEVICE COMPRISING SAME, AND USE THEREOF | July 2021 | March 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17380445 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY, DEVICE COMPRISING SAME, AND USE THEREOF | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17422186 | ANTI-B7S1 POLYPEPTIDES AND THEIR USE | July 2021 | March 2025 | Allow | 45 | 1 | 0 | No | No |
| 17421770 | PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY, DEVICE COMPRISING SAME, AND USE THEREOF | July 2021 | February 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17420537 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR ENHANCING CD8+ T CELL-DEPENDENT IMMUNE RESPONSES IN SUBJECTS SUFFERING FROM CANCER | July 2021 | April 2025 | Abandon | 46 | 2 | 0 | No | No |
| 17418906 | PATHOGEN BINDING PROTEINS | June 2021 | June 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17416829 | NOVEL CYTOKINES AND USE THEREOF | June 2021 | August 2025 | Allow | 49 | 2 | 1 | Yes | No |
| 17415993 | CLAZAKIZUMAB IN THE TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION OF ORGAN TRANSPLANT | June 2021 | May 2025 | Abandon | 47 | 2 | 0 | No | No |
| 17350995 | ANTIBODIES SPECIFIC TO MUC18 | June 2021 | February 2025 | Allow | 44 | 1 | 1 | No | No |
| 17311767 | DIMERIZING AGENT REGULATED IMMUNORECEPTOR COMPLEXES | June 2021 | December 2025 | Abandon | 54 | 3 | 0 | No | No |
| 17297821 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF HER2+ CANCERS | May 2021 | July 2025 | Abandon | 49 | 2 | 0 | Yes | No |
| 17296184 | MODIFIED FC REGION | May 2021 | January 2026 | Allow | 56 | 2 | 1 | Yes | No |
| 17306913 | 14-3-3 ETA Antibodies and Uses Thereof for the Diagnosis and Treatment of Arthritis | May 2021 | December 2024 | Allow | 43 | 3 | 1 | No | No |
| 17287164 | METHODS AND MATERIALS FOR TREATING CANCER | April 2021 | November 2024 | Allow | 43 | 1 | 0 | Yes | No |
| 17177052 | Cryopreserved NK cells preloaded with an antibody construct | February 2021 | November 2025 | Abandon | 57 | 3 | 1 | Yes | No |
| 17267115 | ANTI-IL-1beta ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOF AND USE OF SAME | February 2021 | February 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17258245 | CO-RECEPTOR SYSTEMS FOR TREATING INFECTIOUS DISEASES | January 2021 | December 2024 | Allow | 48 | 3 | 1 | No | No |
| 17251397 | METHODS AND COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR TARGETING CANCER CELLS | December 2020 | October 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17048748 | T CELL RECEPTORS WITH MAGE-B2 SPECIFICITY AND USES THEREOF | October 2020 | September 2024 | Allow | 47 | 1 | 1 | No | No |
| 16999823 | METHODS FOR SCAR PREVENTION | August 2020 | November 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16969056 | CD83-BINDING CHIMERIC ANTIGEN RECEPTORS | August 2020 | June 2025 | Allow | 58 | 2 | 1 | Yes | No |
| 16651531 | METHOD FOR DEPLETING CYTOTOXIC T CELLS USING AN ANTI-LAG-3 ANTIBODY COMPOSITION | March 2020 | July 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16291207 | Treatment of Type 1 Diabetes and Other Conditions Using the Gut Microbiome | March 2019 | September 2021 | Abandon | 31 | 2 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner GUSTILO, ESTELLA M works in Art Unit 1646 and has examined 33 patent applications in our dataset. With an allowance rate of 57.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 48 months.
Examiner GUSTILO, ESTELLA M's allowance rate of 57.6% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by GUSTILO, ESTELLA M receive 1.73 office actions before reaching final disposition. This places the examiner in the 37% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by GUSTILO, ESTELLA M is 48 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +36.4% benefit to allowance rate for applications examined by GUSTILO, ESTELLA M. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 14.3% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.5% of cases where such amendments are filed. This entry rate is in the 56% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants file petitions regarding this examiner's actions, 33.3% are granted (fully or in part). This grant rate is in the 20% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.5% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.